Our study brings to light the potential of the temozolomide–bevacizumab (mTMZ–bevacizumab) regimen in treating metastatic neuroendocrine tumors (NETs) across different tumor grades and Ki-67 proliferation indices. Here, MKI67 is linked to neuroendocrine neoplasm.